205 related articles for article (PubMed ID: 32310036)
1. Biomarkers of Acromegaly and Growth Hormone Action.
Maffezzoni F; Porcelli T; Delbarba A; Pezzaioli L; Cappelli C; Ferlin A
Protein Pept Lett; 2020; 27(12):1231-1245. PubMed ID: 32310036
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
Brabant G
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S15-20. PubMed ID: 12670296
[TBL] [Abstract][Full Text] [Related]
3. What is active acromegaly and which parameters do we have?
Neggers SJ; Biermasz NR; van der Lely AJ
Clin Endocrinol (Oxf); 2012 May; 76(5):609-14. PubMed ID: 22268623
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess.
Ciresi A; Giordano C
Growth Horm IGF Res; 2017 Apr; 33():35-42. PubMed ID: 28372721
[TBL] [Abstract][Full Text] [Related]
5. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.
Giavoli C; Profka E; Verrua E; Ronchi CL; Ferrante E; Bergamaschi S; Sala E; Malchiodi E; Lania AG; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly.
Norrman LL; Johannsson G; Sunnerhagen KS; Svensson J
J Clin Endocrinol Metab; 2008 Jul; 93(7):2531-8. PubMed ID: 18397981
[TBL] [Abstract][Full Text] [Related]
7. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Drake WM; Parkinson C; Besser GM; Trainer PJ
Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
[TBL] [Abstract][Full Text] [Related]
9. Acromegaly induced by growth hormone replacement therapy.
Karges B; Pfäffle R; Boehm BO; Karges W
Horm Res; 2004; 61(4):165-9. PubMed ID: 14707471
[TBL] [Abstract][Full Text] [Related]
10. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
Skjaerbaek C; Frystyk J; Kaal A; Laursen T; Møller J; Weeke J; Jørgensen JO; Sandahl Christiansen J; Orskov H
Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of GH action in children and adults.
Schilbach K; Olsson DS; Boguszewski MCS; Bidlingmaier M; Johannsson G; Jørgensen JL
Growth Horm IGF Res; 2018 Jun; 40():1-8. PubMed ID: 29601998
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load.
Mukai K; Otsuki M; Tamada D; Kitamura T; Hayashi R; Saiki A; Goto Y; Arita H; Oshino S; Morii E; Saitoh Y; Shimomura I
J Clin Endocrinol Metab; 2019 May; 104(5):1637-1644. PubMed ID: 30476255
[TBL] [Abstract][Full Text] [Related]
15. Biochemical investigations in diagnosis and follow up of acromegaly.
Schilbach K; Strasburger CJ; Bidlingmaier M
Pituitary; 2017 Feb; 20(1):33-45. PubMed ID: 28168377
[TBL] [Abstract][Full Text] [Related]
16. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
17. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.
Clemmons DR; Bidlingmaier M
Front Endocrinol (Lausanne); 2023; 14():1266339. PubMed ID: 38027199
[TBL] [Abstract][Full Text] [Related]
18. Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.
Fazeli PK; Teoh JG; Lam EL; Gerweck AV; Wexler TL; Teo EP; Russell BM; Durst R; McCarty D; Weiner RB; Picard MH; Klibanski A; Miller KK
Growth Horm IGF Res; 2016 Feb; 26():17-23. PubMed ID: 26774401
[TBL] [Abstract][Full Text] [Related]
19. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
20. Correlation between GH and IGF-1 during treatment for acromegaly.
Oldfield EH; Jane JA; Thorner MO; Pledger CL; Sheehan JP; Vance ML
J Neurosurg; 2017 Jun; 126(6):1959-1966. PubMed ID: 27858572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
